Maria Alba

VP, Clinical Development at Immunovant

Dr. Maria Alba is Vice President of Clinical Development.

Prior to joining Immunovant, from 2005 to 2019 Maria had spent 6 years at Merck and 8 years at Janssen as Senior Director in Clinical Research, holding key roles and responsibilities in all activities of Phase 2 to Phase 4 clinical development, including the design and implementation of over 20 studies of small and large molecules across multiple indications in the diabetes-metabolism area.

From 2019 to 2020, she was Executive Director at Amicus Therapeutics where she held the position of Global Medical Leader for the entire Phase 2 and 3 clinical program for the development of second generation of enzyme replacement therapy of Pompe disease.

More recently, Maria was Senior Director at Vertex Pharmaceuticals where she led the design and initiation of the First-in-Human study involving the transplant of human stem-cell derived pancreatic islets for the treatment of T1D.

Maria earned an MD from the Catholic University in Rome, Italy, where she also completed her fellowship in Endocrinology and Metabolism.

Location

Berkeley Heights, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Immunovant

6 followers

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.


Industries

Employees

51-200

Links